(Q36172464)

12 August 2017

1 reference

title

Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience (English)

1 reference

12 August 2017

1 reference

1

Robert A Hauser

1 reference

12 August 2017

Michael A Schwarzschild

series ordinal

2

1 reference

PubMed ID

15974638

12 August 2017

language of work or name

1 reference

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

22

1 reference

12 August 2017

6

1 reference

12 August 2017

471-482

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200522060-00002

12 August 2017

0 references

cites work

Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence

1 reference

12 December 2020

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

1 reference

12 December 2020

A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization

1 reference

12 December 2020

A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease

1 reference

12 December 2020

KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse

1 reference

12 December 2020

1 reference

12 December 2020

Functional neuroanatomy of the basal ganglia in Parkinson's disease

1 reference

12 December 2020

Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

1 reference

12 December 2020

Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats

1 reference

12 December 2020

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

1 reference

12 December 2020

Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.

1 reference

12 December 2020

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

1 reference

12 December 2020

The functional anatomy of basal ganglia disorders

1 reference

12 December 2020

The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.

1 reference

12 December 2020

Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor

1 reference

12 December 2020

Association of coffee and caffeine intake with the risk of Parkinson disease

1 reference

12 December 2020

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia

1 reference

12 December 2020

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

1 reference

12 December 2020

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

1 reference

12 December 2020

Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.

1 reference

12 December 2020

Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions

1 reference

12 December 2020

Blockade of A2aAdenosine Receptors Positively Modulates Turning Behaviour and c-Fos Expression Induced by D1Agonists in Dopamine-denervated Rats

1 reference

12 December 2020

Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen.

1 reference

12 December 2020

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

1 reference

12 December 2020

Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats

1 reference

12 December 2020

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

1 reference

12 December 2020

Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.

1 reference

12 December 2020

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

1 reference

12 December 2020

KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity

1 reference

12 December 2020

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

1 reference

12 December 2020

A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice

1 reference

12 December 2020

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

1 reference

12 December 2020

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

1 reference

12 December 2020

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

12 December 2020

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease

1 reference

12 December 2020

SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats

1 reference

12 December 2020

Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study

1 reference

12 December 2020

Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors.

1 reference

12 December 2020

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 December 2020

Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice

1 reference

12 December 2020

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

1 reference

12 December 2020

Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.

1 reference

12 December 2020

Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats

1 reference

12 December 2020

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

12 December 2020

Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen

1 reference

12 December 2020

10.2165/00002512-200522060-00002

Identifiers

DOI

1 reference

PubMed ID

15974638

Dimensions Publication ID

12 August 2017

0 references

1 reference

PubMed ID

15974638